@article {1717,
	title = {In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.},
	journal = {Invest New Drugs},
	volume = {30},
	year = {2012},
	month = {2012 Feb},
	pages = {405-7},
	abstract = {<p>A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) was characterized for anti-lymphoma activity in vivo. For this purpose, a disseminated lymphoma model was generated by intraperitoneal inoculation of BJAB cells in severe combined immunodeficiency mice. Two weekly injections with MB2.23 (10~mg/kg) were able to significantly increase the median survival time of lymphoma-bearing animals with respect to the vehicle-treated control mice, providing a rationale for further investigating the use of MB2.23 in anticancer therapy.</p>},
	keywords = {Animals, Humans, Immunotherapy, Injections, Intraperitoneal, Lymphoma, B-Cell, Mice, Mice, SCID, Receptors, TNF-Related Apoptosis-Inducing Ligand, Single-Chain Antibodies, Time Factors, Xenograft Model Antitumor Assays},
	issn = {1573-0646},
	doi = {10.1007/s10637-010-9519-y},
	author = {Zauli, Giorgio and Corallini, Federica and Zorzet, Sonia and Grill, Vittorio and Marzari, Roberto and Secchiero, Paola}
}
